Preposition: of

• metalloproteinases: Using inhibitors of metalloproteinases to treat arthritis: easier said than done.

• metalloproteinase: As a TIMP ( tissue inhibitor of metalloproteinase ), it also helps mild rheumatoid arthritis.

• reductase: Azelaic acid was also shown to be a potent inhibitor of 5 alpha reductase.

• apoptosis: Other inhibitors that have been identified include a number of inhibitors of apoptosis or " IAPs " .

• kinase: A project to find inhibitors of tyrosine kinase began at Novartis early in the 1980s.

• protease: Inter alia, an assay based on this compound has been used for high-throughput screening to identify inhibitors of the malarial protease.

Adjective modifier

• ace: Several trials have shown that ACE inhibitors improve survival in patients with all grades of heart failure.

• cox-2: The two drugs covered by last year's trials were COX-2 inhibitors.

• monoamine: Sumatriptan must not be used within two weeks of discontinuation of therapy with monoamine oxidase inhibitors.

• selective: Cyclooxygenase 2 selective inhibitors: panacea or flash in the pan?

• non-nucleoside: More recently a number of non-nucleoside reverse transcriptase inhibitors ( NNRTIs ) have been introduced.

• potent: Azelaic acid was also shown to be a potent inhibitor of 5 alpha reductase.

Modifies a noun

• tipranavir: Tipranavir licensed in Europe Boehringer Ingelheim's novel protease inhibitor tipranavir ( Aptivus ) received European approval on 25 October.

• ritonavir: As the body processes them using the same mechanism, the protease inhibitor ritonavir increases levels of methamphetamine to possibly dangerous levels.

Noun used with modifier

• protease: The buzz, of course, was all about protease inhibitors.

• reuptake: Prescribing patterns of selective serotonin reuptake inhibitors in primary care in the United Kingdom.

• serotonin: In the 1990s research for new antidepressant medications focussed on serotonin uptake inhibitors to rival Prozac's phenomenal success.

• reductase: A variety of changes were identified that are common to HMG-CoA reductase inhibitors, viz.

• oxidase: Sumatriptan must not be used within two weeks of discontinuation of therapy with monoamine oxidase inhibitors.

• transcriptase: This medicine contains the active ingredient emtricitabine, which is a type of medicine called a nucleoside reverse transcriptase inhibitor.